Healthy
Conditions
Keywords
PER977, metabolic disposition, mass balance, metabolites, radiolabeled
Brief summary
This is an open-label, single-dose, non-randomized study in healthy male subjects to characterize the mass balance, metabolic disposition, and identification of the metabolites and general metabolic pathways following administration of a single dose of IV solution containing 200 mg of PER977 plus a tracer amount of 14C PER977 in health male subjects.
Interventions
DRUG14C PER977
Open-label, single dose
Sponsors
World Wide Clinical Trials Early Phase Services, LLC
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
15 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male 2. 18-55 years of age (inclusive) 3. Body mass index 18-32 kg/m2 (inclusive) and a minimum of 50 kg (110 lbs) 4. voluntarily consent to participate and provide written informed consent prior to start of study specific procedures 5. Willing and able to remain in the study unit for the entire duration of the confinement period 6. Willing to collect all urine and fecal samples for the duration of the study period as required 7. Will to eat entire meals and snacks provided during confinement at the research facility, and understand diet will include foods with high fiber content and possibly prune juice 8. Willing to use a waterless commode located in a designated dry room for urine and feces collection for the duration of the study period as required 9. Willing to abstain from showering for the first 72 hours following study drug administration. After the restriction is lifted, willing to provide a urine sample prior to showering for the remainder of the confinement period.
Exclusion criteria
1. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any condition which, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results 2. Clinically significant abnormal finding on the physical exam, medical history, electrocardiogram or clinical laboratory resutls at screening 3. History or presence of allergic or adverse response to anticoagulant reversal agents or related drugs 4. Significantly abnormal diet within 4 weeks 5. Donated blood or plasma within 30 days 6. Participated in another clinical trial (randomized subjects only) within 30 days 7. Participated in a radiolabeled clinical trial within the last 12 months 8. Used any over-the-counter medication, including nutritional supplements, within 7 days 9. Used any prescription medication within 14 days prior 10. Treated with any known drugs that are moderate or strong inhibitors/inducers of CYP enzymes such as barbiturates,phenothiazines, cimetidine, carbamazepine, etc. within 30 days 11. Smoked or used tobacco products within 60 days 12. History of substance abuse or treatment (including alcohol ) within the past 2 years 13. Positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates) or cotinine at screening or check-in 14. Positive test for hepatitis B surface antigen, hepatitis C antibody or human immunodeficiency virus at screening or has previously been treated for hepatitis B, hepatitis C or HIV infection 15. Has irregular bowel habits 16. Has had significant radiation exposure within the prior 12 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mass balance of PER977 and metabolite | 3 weeks | To characterize the mass balance, metbaolic disposition, and identification of the metabolites and general metabolic pathways following administration of a single dose of IV solution containing 200 mg of PER977 plus a tracer amount of 14C PER977 to healthy male subjects |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with adverse events | 3 weeks | To assess the safety and tolerability of a single intravenous dose of 200 mg PER977 |
Countries
United States
Outcome results
None listed